A Study of LG00313112 in People With Solid Tumor Cancer

Full Title

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants with Advanced Solid Malignancies Harboring a TP53 Y220C mutation

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Alison Schram’s office at 646-888-4226.

Protocol
26-379
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07752875